December 2025
Disclosure Roundup

Regulatory agency updates for December 2025 include ISRCTN's application form guidance with Rapid Registration Checklist; Slovakia 艩脷KL's beta website launch with H2 2026 full transition; Romania's national platform for real-time CTIS data in Romanian; and Austria BASG's increased fee schedule effective Jan. 1, 2026.

 
Key updates this month

The ISRCTN published application form guidance following enhancements to its website. The guidance explains the data fields required for study registration. It covers five sections: Study Overview, Information for Participants, Contacts/Sponsor/Funder/Ethics, Uploads/Outputs, and Payment. Additionally, a Rapid Registration Checklist is provided to expedite the submission process.

The State Institute for Drug Control (艩脷KL) launched a trial version of its website at beta.sukl.sk to improve user experience, modernize design, and enhance accessibility. Full transition from the current www.sukl.sk to the new platform is planned for the second half of 2026.

The National Agency for Medicines and Medical Devices (NAMMDR) has launched a national platform (https://studiiclinice.anm.ro/) that provides real-time access to CTIS data in Romanian, classified by therapeutic areas and geographical distribution. The platform serves as an informational and educational tool for patients, physicians, and the medical community to identify ongoing clinical trials in Romania.

The Federal Office for Safety in Health Care (BASG) implemented a revised clinical trial fee schedule effective Jan. 1, 2026. Phase I鈥揑II fee notification increased to 鈧�4,081, Phase IV to 鈧�2,052, and substantial modifications to 鈧�679. Under the EU CTR (Regulation 536/2014), BASG assessment fees now range 鈧�1,392鈥撯偓6,074, Ethics Committee fees 鈧�821鈥撯偓4,112, and substantial modification fees 鈧�569鈥撯偓1,076 (BASG) and 鈧�886 (Ethics Committee).

Darkened Qualified calendar. Please allow all cookies to use functionality.

To enable the booking feature, please enable all cookies in your browser.